Psychiatric Disorders

Does Long-Term Benzodiazepine Use Up Mortality in COPD, PTSD?

October 18, 2018

No difference in mortality, but risk for suicide elevated with long-term benzodiazepine use

Novel Narcolepsy Treatment Gets Orphan Drug Designation

By October 18, 2018

The Company stated that they plan to begin a Phase 2 trial of AXS-12 before the end of 2018, with results anticipated for the first half of 2019.

Positive Results for Lemborexant in Insomnia Disorder Study

By October 17, 2018

SUNRISE 2 is an ongoing long-term efficacy and safety study (N=900) of adults (aged 18 to 88 years) with insomnia disorder who have difficulty falling and/or staying asleep.

Dose Range of IV Ketamine for Adjunct Tx of Depression Tested

October 17, 2018

Compared with the active placebo, the infusions of ketamine were relatively well tolerated, except for greater dissociative symptoms and transient blood pressure elevations with the higher doses.

Sexual Harassment, Assault Tied to Women's Health Issues

October 05, 2018

Among women not taking antihypertensives, sexual harassment was correlated with significantly increased odds of stage 1 or 2 hypertension (odds ratio, 2.36) as well as clinically poor sleep (odds ratio, 1.89) after adjustment for covariates.

Abuse of Antidepressant for Weight Loss Leads to Seizures in Patient With Bulimia Nervosa

By October 03, 2018

The patient obtained prescriptions for bupropion XR from psychiatrists and primary care physicians who were not aware of her past medical history.

High HbA1c After T1DM Diagnosis Predicts Psychiatric Comorbidity

October 03, 2018

Higher risk for psychiatric diagnoses was predicted by high average HbA1c levels during the first 2 years of diabetes onset.

Global Cognition Up for Youth Meeting Movement Guidelines

October 02, 2018

The researchers found that the mean number of guidelines met was 1.1; 51, 37, and 18% of participants met the daily recommendations for sleep time (9 to 11 hours/night), screen time (2 hours or less), and physical activity (60 minutes or more), respectively.

NDA Submitted for Novel Schizophrenia Treatment Lumateperone

By September 28, 2018

Lumateperone, a first-in-class molecule, works via potent interactions at 5-HT2A receptors, serotonin transporters, and D1 receptors with indirect glutamatergic modulation.

Researchers Recommend Reclassification of Psilocybin

By September 27, 2018

Currently, psilocybin, a serotonin receptor agonist, is classified as a Schedule I agent as it has not been approved by the Food and Drug Administration (FDA) for any therapeutic use.

FDA to Review Vraylar sNDA for Treatment of Bipolar Depression

By September 26, 2018

The sNDA included findings from the RGH-MD-53, RGH-MD-54, and RGH-MD-56 trials in which cariprazine was associated with greater improvement in change from baseline to week 6 on the Montgomery Asberg Depression Rating scale (MADRS) total score vs placebo in bipolar I patients.

Psychiatric Adverse Effects of Disease-Modifying Therapies Assessed in MS Patients

By September 25, 2018

The primary outcome measure of the study was the frequency of any adverse psychiatric effect observed during treatment with one of these agents.

High-Risk Anticholinergics Prescribed to Six Percent of Elderly

September 25, 2018

The researchers found that a high-risk anticholinergic prescription was listed for 6.2% of visits of older adults between 2006 and 2015, representative of 14.6 million total visits nationally.

FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid

By September 21, 2018

Based on the data, the FDA has concluded that the drug's benefit continues to outweigh its risks for patients with hallucinations and delusions associated with Parkinson's disease psychosis.

Many Foster Kids Inappropriately Prescribed Psychiatric Drugs

September 18, 2018

A report from the Department of Health and Human Services (HHS) found that 1 in 3 foster children sampled in 5 states received the drugs without treatment plans or follow-up.

Many Older Adults Transition to Long-Term Benzodiazepine Use

September 14, 2018

The researchers found that 26.4% of adults met the definition of long-term use 1 year after the index prescription; they were prescribed a mean of 232.7 benzodiazepine days.

Physician Burnout Rates Vary by Medical Specialty

September 11, 2018

Nearly half of those in critical care, neurology, family medicine, ob-gyn, internal medicine report burnout

Treating Older Adult Bipolar Disorder: Newer Atypical Antipsychotics Compared

By September 10, 2018

While pharmacologic agents such as lithium and valproic acid have been shown to provide significant antimanic effects in older adults with bipolar disorder, an increase in the use of atypical antipsychotics in the general adult bipolar population prompted researchers to investigate the efficacy and tolerability of these agents in OABD.

Physician burn-out linked to patient safety incidents, low patient satisfaction

September 08, 2018

In this meta-analysis of available studies, physician burnout was linked to an increased risk of patient safety incidents, professionalism issues, and reduced patient satisfaction.

Guidelines for Managing Perimenopausal Depression Now Available

By September 05, 2018

The 5 topics addressed by the 11-member expert panel include epidemiology, clinical presentation, therapeutic effects of antidepressants, effects of hormone therapy, and the effectiveness of other therapies (eg, psychotherapy, exercise, natural health products).

Esketamine Nasal Spray NDA Submitted to FDA for Treatment-Resistant Depression

By September 04, 2018

The NDA includes five Phase 3 studies in patients with treatment-resistant depression: 3 short-term studies, 1 withdrawal maintenance of effect study, and 1 long-term safety study.

Self-Injury Tops Diabetes As Cause of Death in United States

September 04, 2018

The researchers found that in 2015, SIM surpassed diabetes as a cause of death in the United States. In 2016, the gap expanded, with rates of 29.1 and 24.8 per 100,000 population, respectively.

Risk of Depression Up in Autism Spectrum Disorder

September 04, 2018

The researchers found that by age 27 years, 19.8% of individuals diagnosed with ASD had a diagnosis of depression, compared with 6.0% among the general population (adjusted relative risk [RR], 3.64).

FDA Rejects ADHD Drug NDA Citing Need for More Data

By August 31, 2018

The FDA stated that the dasotraline NDA cannot be approved in its current form and is requiring additional data to further assess the efficacy and tolerability of the drug.

Psychosis Treatments

August 30, 2018

A comparative dosing and titration chart of commonly used first-generation and second-generation antipsychotics.

Psychotropic Drug Indications

August 30, 2018

A comparative list of psychotropic medications with their mood disorder indications (bipolar disorder, major depressive disorder, treatment resistant depression, premenstrual dysphoric disorder, and others).

Lithium Efficacy, Safety Examined in Children, Adolescents With Bipolar Disorder

By August 27, 2018

With regard to safety, treatment with lithium in this patient population was considered "generally safe, at least in the short term."

Psilocybin Study Gets Green Light From FDA for Treatment-Resistant Depression

By August 22, 2018

The trial will be a Phase 2b dose-ranging study (N=216) with patients from 12-15 research centers across Europe and North America.

Midlife Deaths Increase in the United States

August 20, 2018

The researchers found that all-cause mortality increased among non-Hispanic (NH) whites, NH American Indians, and Alaskan Natives.

TMS Device Cleared to Treat Obsessive Compulsive Disorder

By August 17, 2018

Transcranial magnetic stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain.